捷迈邦美 2026年季度报告

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THESECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED March 31, 2026 Commission File Number 001-16407 ZIMMER BIOMET HOLDINGS, INC. (Exact name of registrant as specified in its charter) Delaware(State or other jurisdiction ofincorporation or organization) 13-4151777(IRS EmployerIdentification No.) 345 East Main Street, Warsaw, IN 46580(Address of principal executive offices)Telephone: (574) 373-3333 Securities registered pursuant to Section 12(b) of the Act: Name of each exchange on which registeredNew York Stock Exchange Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the SecuritiesExchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file suchreports), and (2) has been subject to such filing requirements for the past 90 days.Yes☒No☐ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submittedpursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period thatthe registrant was required to submit such files).Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smallerreporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smallerreporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. Large accelerated filer☒Non-accelerated filer☐Emerging growthcompany☐ Accelerated filer If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period forcomplying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes☐No☒ As of April 23, 2026, 193,462,482 shares of the registrant’s $.01 par value common stock were outstanding. ZIMMER BIOMET HOLDINGS, INC.INDEX TO FORM 10-QMarch 31, 2026 Part I - Financial Information Item 1.Financial Statements (unaudited)3Condensed Consolidated Statements of Earnings for the Three Months Ended March 31, 2026 and 20253Condensed Consolidated Statements of Comprehensive Income for the Three Months Ended March 31, 2026and 20254Condensed Consolidated Balance Sheets as of March 31, 2026 and December 31, 20255Condensed Consolidated Statements of Stockholders’ Equity for the Three Months Ended March 31, 2026and 20256Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 20257Notes to Interim Condensed Consolidated Financial Statements8Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations27Item 3.Quantitative and Qualitative Disclosures About Market Risk34Item 4.Controls and Procedures34Part II - Other InformationItem 1.Legal Proceedings36Item 1A.Risk Factors36Item 2.Unregistered Sales of Equity Securities and Use of Proceeds36Item 3.Defaults Upon Senior Securities36Item 4.Mine Safety Disclosures36Item 5.Other Information36Item 6.Exhibits37Signatures38 ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF EARNINGS(in millions, except per share amounts, unaudited) ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME(in millions, unaudited) ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(in millions, except share amounts, unaudited) ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY(in millions, except per share amounts, unaudited) The accompanying notes are an integral part of these condensed consolidated financial statements. ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(in millions, unaudited) ZIMMER BIOMET HOLDINGS, INC. AND SUBSIDIARIESNOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1. Basis of Presentation The financial data presented herein is unaudited and should be read in conjunction with the consolidated financial statementsand accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025, filed on February 20,2026. In our opinion, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting ofonly normal recurring adjustments, necessary for a fair statement of the financial position, results of operations and cash flows forthe interim periods presented. The December 31, 2025 condensed consolidated balance sheet data was derived from auditedfinancial statements, but does not include all disclosures required by accounting principles generally accepted